Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale - Revised for fragile X syndrome

American Journal on Intellectual and Developmental Disabilities

Volumn 119, Issue 1, 2014, Pages 1-16

  Russo Ponsaran, Nicole M ^a   Yesensky, Jessica ^a   Hessl, David ^b   Berry Kravis, Elizabeth ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anxiety; Fragile X syndrome; Outcome measure; Rating scale

Indexed keywords

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; FEASIBILITY STUDY; FEMALE; FRAGILE X SYNDROME; HUMAN; MALE; PILOT STUDY; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REPRODUCIBILITY; STANDARD; STATISTICS; VALIDATION STUDY;

ADOLESCENT; ADULT; ANXIETY DISORDERS; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; FEASIBILITY STUDIES; FEMALE; FRAGILE X SYNDROME; HUMANS; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS;

EID: 84893034152     PISSN: 19447515     EISSN: 19447558     Source Type: Journal    
DOI: 10.1352/1944-7558-119.1.1     Document Type: Article

References (56)

1. Achenbach, T. (1991). Manual for the child behavior checklist/4-18 & 1991 profile. Burlington, VT: University of Vermont.
2. Albano, A.M., & Silverman, W. K. (1996). The Anxiety Disorders Interview Schedule for Children for DSM-IV: Clinician Manual (Child and Parent Versions). San Antonio, TX: Psychological Corporation.
3. Aman, M. G., and Burrow, W. H., & Wolford, P. L. (1995). The aberrant behavior checklist-community: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100(3), 293-292.
4. Aman, M. G., and Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485-491.
5. Amaria, R. N., and Billeisen, L. L., & Hagerman, R. (2001). Medication use in fragile X syndrome. Mental Health Aspects of Developmental Disabilities, 4(4), 143-147.
6. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
7. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
8. Berry-Kravis, E., Krause, S. E., and Block, S. S., Guter, S., Wuu, J., Leurgans, S., Hagerman, R. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial. Journal of Child and Adolescent Psychopharmacology, 16(5), 525-540. doi:10.1089/cap.2006. 16.525
9. Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome - Present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 42-48. doi:10.1002/mrdd.20007
10. Berry-Kravis, E., Sumis, A., Hervey, C., & Mathur, S. (2012). Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome. International Journal of Pediatrics, 2012, 843016. doi:10.1155/2012/843016
11. Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Greenough, W. T. (2008). Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. Journal of Developmental and Behavioral Pediatrics, 29(4), 293-302. doi:10.1097/DBP.0b013e31817dc447
12. Birmaher, B., and Axelson, D. A., Monk, K., Kalas, C., Clark, D. B., Ehmann, M., Brent, D. A. (2003). Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 42(4), 415-423. doi:10.1097/01. CHI.0000037049.04952.9F
13. Bowling, A. (2005). Mode of questionnaire administration can have serious effects on data quality. Journal of Public Health (Oxford), 27(3), 281-291. doi:10.1093/pubmed/fdi031
14. Cicchetti, D. V., & Sparrow, S. A. (1981). Developing criteria for establishing interrater reliability of specific items: Applications of assessment of adaptive behavior. American Journal of Mental Deficiency, 86(2), 127-137.
15. Cordeiro, L., Ballinger, E., Hagerman, R., & Hessl, D. (2011). Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. Journal of Neurodevelopmental Disorders, 3(1), 57-67. doi:10.1007/s11689-010-9067-y
16. Esbensen, A. J., Rojahn, J., Aman, M. G., & Ruedrich, S. (2003). Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. Journal of Autism and Developmental Disorders, 33(6), 617-629. doi:10.1023/B:JADD.0000005999.27178.55
17. Fletcher, R., Loschen, E., Stavrakaki, C., & First, M. (2007). Diagnostic manual-intellectual disability (DM-ID): A textbook of diagnosis of mental disorders in persons with intellectual disability. Kingston, NY: NADD Press.
18. Forkmann, T., Scherer, A., Boecker, M., Pawelzik, M., Jostes, R., & Gauggel, S. (2011). The clinical global impression scale and the influence of patient or staff perspective on outcome. BMC Psychiatry, 11, 83. doi:10. 1186/1471-244X-11-83
19. Freund, L. S., and Reiss, A. L., & Abrams, M. T. (1993). Psychiatric disorders associated with fragile X in the young female. Pediatrics, 91(2), 321-329.
20. Geller, D., Donnelly, C., Lopez, F., Rubin, R., Newcorn, J., Sutton, V., Sumner, C. (2007). Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46(9), 1119-1127. doi:10.1097/chi.0b013e3180ca8385
21. Greenhill, L. L., Pine, D., March, J., Birmaher, B., & Riddle, M. (1998). Assessment issues in treatment research of pediatric anxiety disorders: What is working, what is not working, what is missing, and what needs improvement. Psychopharmacology Bulletin, 34(2), 155-164.
22. Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., and Ono, M. Y., Tartaglia, N., Lachiewicz, A., Tranfaglia, M. (2009). Advances in the treatment of fragile X syndrome. Pediatrics, 123(1), 378-390. doi:10.1542/peds.2008-0317
23. Hagerman, R. J., and Fulton, M. J., Leaman, A., & Riddle, J. (1994). A survey of fluoxetine therapy in fragile X syndrome. Developmental Brain Dysfunction, 7(2-3), 155-164.
24. Hagerman, R., Lauterborn, J., Au, J., & Berry-Kravis, E. (2012). Fragile X syndrome and targeted treatment trials. Results and Problems in Cell Differentiation, 54, 297-335. doi:10. 1007/978-3-642-21649-7-17
25. Hall, S. S., and Lightbody, A. A., Huffman, L. C., Lazzeroni, L. C., & Reiss, A. L. (2009). Physiological correlates of social avoidance behavior in children and adolescents with fragile x syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 48(3), 320-329. doi:10.1097/CHI. 0b013e318195bd15
26. Hermans, H., van der Pas, F. H., & Evenhuis, H. M. (2011). Instruments assessing anxiety in adults with intellectual disabilities: A systematic review. Research in Developmental Disabilities, 32(3), 861-870. doi:10.1016/j.ridd.2011.01.034
27. Horovitz, M., and Matson, J. L., Sipes, M., Shoemaker, M., Belva, B., & Bamburg, J. W. (2011). Incidence and trends in psychopathology symptoms over time in adults with severe to profound intellectual disability. Research in Developmental Disabilities, 32(2), 685-692. doi:10.1016/j.ridd.2010.11.013
28. Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Gomez-Mancilla, B. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine, 3(64), 64ra1. doi:10.1126/scitranslmed.3001708
29. Keysor, C. S., & Mazzocco, M. M. (2002). A developmental approach to understanding fragile X syndrome in females. Microscopy Research and Technique, 57(3), 179-186. doi:10.1002/jemt.10070
30. Lachiewicz, A. M. (1992). Abnormal behaviors of young girls with fragile X syndrome. American Journal of Medical Genetics, 43(1-2), 72-77.
31. Lachiewicz, A. M., & Dawson, D. V. (1994). Behavior problems of young girls with fragile X syndrome: Factor scores on the Conners' Parent's Questionnaire. American Journal of Medical Genetics, 51(4), 364-369. doi:10.1002/ajmg.1320510413
32. Lachiewicz, A., Dawson, D., Spiridigliozzi, G., Cuccaro, M., Lachiewicz, M., & McConkie-Rosell, A. (2010). Indicators of anxiety and depression in women with the fragile X premutation: Assessment of a clinical sample. Journal of Intellectual Disability Research, 54(7), 597-610. doi:10.1111/j.1365-2788. 2010.01290.x
33. Langer, D. A., and Wood, J. J., Bergman, R. L., & Piacentini, J. C. (2010). A multitrait-multi-method analysis of the construct validity of child anxiety disorders in a clinical sample. Child Psychiatry and Human Development, 41(5), 549-561. doi:10.1007/s10578-010-0187-0
34. Lesniak-Karpiak, K., Mazzocco, M. M., & Ross, J. L. (2003). Behavioral assessment of social anxiety in females with Turner or fragile X syndrome. Journal of Autism and Developmental Disorders, 33(1), 55-67.
35. Levitas, A. (1996). Neuropsychiatric aspects of fragile X syndrome. Seminars in Clinical Neuropsychiatry, 1(2), 154-167. doi:10.1053/SCNP00100154
36. Loesch, D. Z., and Huggins, R. M., & Hagerman, R. J. (2004). Phenotypic variation and FMRP levels in fragile X. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 31-41. doi:10.1002/mrdd. 20006
37. Matson, J. L., and Smiroldo, B. B., Hamilton, M., & Baglio, C. S. (1997). Do anxiety disorders exist in persons with severe and profound mental retardation? Research in Developmental Disabilities, 18(1), 39-44.
38. Mazzocco, M. M. M., Baumgardner, T., Freund, L. S., & Reiss, A. L. (1998). Social functioning among girls with fragile X or Turner syndrome and their sisters. Journal of Autism and Developmental Disorders, 28(6), 509-517. doi:10. 1023/A:1026000111467
39. Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., and Ethell, I. M., & Ethell, D. W. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurology, 10, 91. doi:10.1186/1471- 2377-10-91
40. Reynolds, W. M. (1999). Multidimensional Anxiety Questionnaire. Odessa, FL: Psychological Assessment Resources.
41. Riddle, M. A., Ginsburg, G., Palapattu, A., & Walkup, J. (2004). Pediatric Anxiety Rating Scale-Revised (PARS-R). Baltimore, MD: Johns Hopkins Medical Institutions.
42. Riddle, M. A., and Ginsburg, G. S., Walkup, J. T., Labellarte, M. J., and Pine, D. S., Davies, M., Roper, M. (2002). The pediatric anxiety rating scale (PARS): Development and psychometric properties. Journal of the American Academy of Child & Adolescent Psychiatry, 41(9), 1061-1069. doi:10.1097/00004583- 200209000-00006
43. Roberts, J. E., and Weisenfeld, L. A., Hatton, D. D., Heath, M., & Kaufmann, W. E. (2007). Social approach and autistic behavior in children with fragile X syndrome. Journal of Autism and Developmental Disorders, 37(9), 1748-1760. doi:10.1007/s10803-006-0305-9
44. Rojahn, J., and Rowe, E. W., Kasdan, S., Moore, L., & van Ingen, D. J. (2011). Psychometric properties of the aberrant behavior checklist, the anxiety, depression and mood scale, the assessment of dual diagnosis and the social performance survey schedule in adults with intellectual disabilities. Research in Developmental Disabilities, 32(6), 2309-2320. doi:10. 1016/j.ridd.2011.07.035
45. Rutter, M., Le Couteur, A., & Lord, C. (2003). ADI-R: The autism diagnostic interview-revised. Los Angeles, CA: Western Psychological Services.
46. Sansone, S. M., and Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., and Kaufmann, W. E., Hessl, D. (2011). Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. Journal of Autism and Developmental Disorders, 42(7), 1377-1392. doi:10.1007/s10803-011-1370-2
47. Silverman, W. K., and Saaverdra, L. M., & Pina, A. A. (2001). Test-retest reliability of anxiety symptoms and diagnoses with the Anxiety Disorders Interview Schedule for DSM-IV: Child and parent versions. Journal of the American Academy of Child & Adolescent Psychiatry, 40(8), 937-944.
48. Storch, E. A., and Wood, J. J., Ehrenreich-May, J., Jones, A. M., and Park, J. M., Lewin, A. B., & Murphy, T. K. (2012). Convergent and discriminant validity and reliability of the Pediatric Anxiety Rating Scale in youth with autism spectrum disorders. Journal of Autism and Developmental Disorders, 42(11), 2374-2382. doi:10.1007/s10803-012-1489-9
49. Sudhalter, V., & Belser, R. C. (2001). Conversational characteristics of children with fragile X syndrome: Tangential language. American Journal of Mental Retardation, 106(5), 389-400.
50. Sullivan, K., Hooper, S., & Hatton, D. (2007). Behavioural equivalents of anxiety in children with fragile X syndrome: Parent and teacher report. Journal of Intellectual Disability Research, 51(Pt. 1), 54-65. doi:10.1111/j.1365-2788.2006.00899.x
51. Tassone, F., and Hagerman, R. J., Ikle, D. N., Dyer, P. N., Lampe, M., Willemsen, R., Taylor, A. K. (1999). FMRP expression as a potential prognostic indicator in fragile X syndrome. American Journal of Medical Genetics, 84(3), 250-261.
52. Turk, J. (2011). Fragile X syndrome: Lifespan developmental implications for those without as well as with intellectual disability. Current Opinion in Psychiatry, 24(5), 387-339.
53. Walkup, J. T., and Labelarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Roper, M. (2001). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The research unit on pediatric psychopharmacology anxiety study group. New England Journal of Medicine, 344(17), 1279-1285. doi:10.1056/NEJM200104263441703
54. Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010). Fragile X: Leading the way for targeted treatments in autism. Neurotherapeutics, 7(3), 264-274. doi:10.1016/j.nurt.2010.05.005
55. Ward-King, J., Cohen, I. L., Penning, H., & Holden, J. J. A. (2010). Brief report: Telephone administration of the autism diagnostic interview - Revised: Reliability and suitability for use in research. Journal of Autism and Developmental Disorders, 40(10), 1285-1290. doi:10.1007/s10803-010-0987-x
56. Wolff, P. H., Gardner, J., Lappen, J., Paccia, J., & Meryash, D. (1988). Variable expression of the fragile X syndrome in heterozygous females of normal intelligence. American Journal of Medical Genetics, 30(1-2), 213-225.